Get the Stockscreener App
66.95
0.15%
-0.10
After Hours:
66.92
-0.03
-0.04%
Axonics Inc stock is currently priced at $66.95, with a 24-hour trading volume of 560.20K.
It has seen a -0.15% decreased in the last 24 hours and a -2.55% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $67.12 pivot point. If it approaches the $66.90 support level, significant changes may occur.
Axonics Inc Stock (AXNX) Financials Data
Axonics Inc (AXNX) Revenue 2024
AXNX reported a revenue (TTM) of $366.38 million for the quarter ending December 31, 2023, a +33.86% rise year-over-year.
Axonics Inc (AXNX) Net Income 2024
AXNX net income (TTM) was -$6.09 million for the quarter ending December 31, 2023, a +89.80% increase year-over-year.
Axonics Inc (AXNX) Cash Flow 2024
AXNX recorded a free cash flow (TTM) of -$5.57 million for the quarter ending December 31, 2023, a -675.00% decrease year-over-year.
Axonics Inc (AXNX) Earnings per Share 2024
AXNX earnings per share (TTM) was -$0.13 for the quarter ending December 31, 2023, a +90.00% growth year-over-year.
Axonics Inc Stock (AXNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Noblett Karen | Chief Medical Officer |
Jan 31 '24 |
Option Exercise |
0.00 |
27,500 |
0 |
45,716 |
| Sama Rinda | Chief Operating Officer |
Jan 31 '24 |
Option Exercise |
0.00 |
28,000 |
0 |
83,854 |
| Woock John | EVP, Chief Mktg/Strtgy Officer |
Jan 31 '24 |
Option Exercise |
0.00 |
28,000 |
0 |
93,302 |
| Ford Alfred J Jr | Chief Commercial Officer |
Jan 31 '24 |
Option Exercise |
0.00 |
25,500 |
0 |
60,065 |
| COHEN RAYMOND W | Chief Executive Officer |
Jan 31 '24 |
Option Exercise |
0.00 |
63,400 |
0 |
223,996 |
| Keese Kari Leigh | Chief Financial Officer |
Jan 31 '24 |
Option Exercise |
0.00 |
6,167 |
0 |
46,812 |
| COHEN RAYMOND W | Chief Executive Officer |
Jan 31 '24 |
Sale |
67.74 |
35,161 |
2,381,662 |
188,835 |
| Ford Alfred J Jr | Chief Commercial Officer |
Jan 31 '24 |
Sale |
67.74 |
16,615 |
1,125,432 |
43,450 |
| Woock John | EVP, Chief Mktg/Strtgy Officer |
Jan 31 '24 |
Sale |
67.74 |
15,899 |
1,076,933 |
77,403 |
| Noblett Karen | Chief Medical Officer |
Jan 31 '24 |
Sale |
67.74 |
11,288 |
764,603 |
34,428 |
Axonics Inc Stock (AXNX) Latest News
All You Need to Know About Axonics (AXNX) Rating Upgrade to Buy
Zacks Investment Research
Axonics (AXNX) Gets CE Mark for Sacral Neuromodulation System
Zacks Investment Research
Beyond The Numbers: 7 Analysts Discuss Axonics Stock
Benzinga
Axonics Modulation Technologies (AXNX) Q4 Earnings and Revenues Surpass Estimates
Zacks Investment Research
American Well Corporation (AMWL) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Zacks.com featured highlights include Axonics, Enerpac Tool Group, Cardinal Health and Acuity Brands
Zacks Investment Research
About Axonics Inc
Axonics Modulation Technologies, Inc., a medical technology company, focuses on the design, development, and commercialization of sacral neuromodulation solutions (SNM) solutions. The SNM therapy is primarily used to treat patients with overactive bladder, fecal incontinence, and urinary retention. The company was formerly known as American Restorative Medicine, Inc. and changed its name to Axonics Modulation Technologies, Inc. in August 2013. Axonics Modulation Technologies, Inc. was incorporated in 2012 and is based in Irvine, California.
COMPANY PROFILE
NameAxonics Inc
SectorHealthcare (1201)
IndustryMedical Devices (158)
Web
Phone949-396-6322
Employee72
Twitter
@axonics_mod
SEC filings
Latest SEC Filings
Next earning date2024-04-29
Address26 Technology Drive, Irvine, CA, United States (92618)
0.00%
0.65%
Cap:
|
Volume (24h):